# Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer

> **NCT00635726** · PHASE2 · TERMINATED · sponsor: **Hellenic Oncology Research Group** · enrollment: 41 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **DRUG:** Methotrexate
- **DRUG:** Vinblastine
- **DRUG:** Doxorubicin
- **DRUG:** Cisplatin
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT00635726
- **Lead sponsor:** Hellenic Oncology Research Group
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-02
- **Primary completion:** 2013-02
- **Final completion:** 2013-02
- **Target enrollment:** 41 (ACTUAL)
- **Why stopped:** Due to poor accrual
- **Last updated:** 2015-10-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00635726

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00635726, "Methotrexate, Vinblastine, Doxorubicin and Cisplatin (MVAC) Followed by Gemcitabine Plus Cisplatin (GEM+CDDP) in Locally Advanced or Metastatic Bladder Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00635726. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*